Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03914612

Recruitment Status : Active, not recruiting

First Posted : April 16, 2019

Last Update Posted : May 16, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Canadian Cancer Trials Group

NRG Oncology

Information provided by (Responsible Party):

National Cancer Institute (NCI)

Results Submitted - Quality Control (QC) Review Has Not Concluded

Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	December 16, 2022
Estimated Study Completion Date :	May 10, 2024

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	January 9, 2024	February 1, 2024 Submission with QC Comments

To Top